CN111163771B - 嘧啶并嘧啶酮类作为sik抑制剂的用途 - Google Patents

嘧啶并嘧啶酮类作为sik抑制剂的用途 Download PDF

Info

Publication number
CN111163771B
CN111163771B CN201880027619.8A CN201880027619A CN111163771B CN 111163771 B CN111163771 B CN 111163771B CN 201880027619 A CN201880027619 A CN 201880027619A CN 111163771 B CN111163771 B CN 111163771B
Authority
CN
China
Prior art keywords
substituted
unsubstituted
instance
alkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880027619.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN111163771A (zh
Inventor
D.E.菲舍尔
N.穆贾希德
N.S.格雷
梁焱科
村上亮
崔焕根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Dana Farber Cancer Institute Inc
Original Assignee
General Hospital Corp
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Dana Farber Cancer Institute Inc filed Critical General Hospital Corp
Publication of CN111163771A publication Critical patent/CN111163771A/zh
Application granted granted Critical
Publication of CN111163771B publication Critical patent/CN111163771B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201880027619.8A 2017-02-28 2018-02-28 嘧啶并嘧啶酮类作为sik抑制剂的用途 Active CN111163771B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762464675P 2017-02-28 2017-02-28
US62/464,675 2017-02-28
US201762472468P 2017-03-16 2017-03-16
US62/472,468 2017-03-16
PCT/US2018/020335 WO2018160774A1 (en) 2017-02-28 2018-02-28 Uses of pyrimidopyrimidinones as sik inhibitors

Publications (2)

Publication Number Publication Date
CN111163771A CN111163771A (zh) 2020-05-15
CN111163771B true CN111163771B (zh) 2023-07-14

Family

ID=63370223

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880027619.8A Active CN111163771B (zh) 2017-02-28 2018-02-28 嘧啶并嘧啶酮类作为sik抑制剂的用途

Country Status (10)

Country Link
US (3) US11285158B2 (enExample)
EP (1) EP3589284A4 (enExample)
JP (2) JP7296318B2 (enExample)
KR (1) KR20190120331A (enExample)
CN (1) CN111163771B (enExample)
AU (1) AU2018226771B2 (enExample)
BR (1) BR112019017741A2 (enExample)
CA (1) CA3054809A1 (enExample)
RU (1) RU2019129727A (enExample)
WO (1) WO2018160774A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015292818B2 (en) 2014-07-21 2020-01-16 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
CA3069016A1 (en) 2016-07-05 2018-01-11 The Broad Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
WO2018053373A1 (en) 2016-09-16 2018-03-22 The General Hospital Corporation Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis
AU2018226771B2 (en) * 2017-02-28 2023-11-23 Dana-Farber Cancer Institute, Inc. Uses of pyrimidopyrimidinones as SIK inhibitors
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US20230048132A1 (en) * 2018-12-28 2023-02-16 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
IL287795B2 (en) 2019-05-10 2025-05-01 Deciphera Pharmaceuticals Llc Heteroarylaminopyrimidine amides as autophagy inhibitors and methods of using them
CN118878519A (zh) 2019-05-10 2024-11-01 德西费拉制药有限责任公司 苯基氨基嘧啶酰胺自噬抑制剂及其使用方法
WO2020257180A1 (en) * 2019-06-17 2020-12-24 Deciphera Pharmaceuticals, Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof
TW202115024A (zh) 2019-08-14 2021-04-16 美商英塞特公司 作為cdk2 抑制劑之咪唑基嘧啶基胺化合物
CN119930610A (zh) 2019-10-11 2025-05-06 因赛特公司 作为cdk2抑制剂的双环胺
EP3901151A1 (en) 2020-04-21 2021-10-27 iOmx Therapeutics AG Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof
EP4143191A2 (en) 2020-04-28 2023-03-08 iOmx Therapeutics AG Bicyclic kinase inhibitors and uses thereof
WO2022061312A1 (en) * 2020-09-21 2022-03-24 Soltego, Inc. Sik inhibitors and methods of use thereof
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US20250296928A1 (en) 2021-10-19 2025-09-25 Iomx Therapeutics Ag A synthesis scheme and procedures for preparing a sik3 inhibitor and intermediates thereof
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN114414681B (zh) * 2021-12-30 2024-10-11 珠海天祥粤澳质量技术服务有限公司 一种同时测定化妆品中的多种色素的方法
EP4257132A1 (en) 2022-04-08 2023-10-11 iOmx Therapeutics AG Sik3 inhibitors for treating diseases resistant to death receptor signalling
JP2025517351A (ja) * 2022-05-17 2025-06-05 ソルテゴ， インコーポレイテッド ピリミドピリミドン化合物およびその使用方法
WO2025059216A1 (en) * 2023-09-12 2025-03-20 Dana-Farber Cancer Institute, Inc. Treatment of high-grade serous carcinoma
WO2025157389A1 (en) 2024-01-22 2025-07-31 Iomx Therapeutics Ag Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors
CN118546871B (zh) * 2024-05-10 2025-05-06 未来智人再生医学研究院(广州)有限公司 一种人多能干细胞分化为间充质干细胞的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014093383A1 (en) * 2012-12-14 2014-06-19 Arrien Pharmaceuticals Llc Substituted 1h-pyrrolo [2,3-b] pyridine and 1h-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (sik2) inhibitors
WO2016023014A2 (en) * 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Uses of salt-inducible kinase (sik) inhibitors

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4231559B2 (ja) 1997-04-23 2009-03-04 オリザ油化株式会社 リポキシゲナーゼ阻害剤
EE200000706A (et) 1998-05-26 2002-06-17 Warner-Lambert Company Bitsüklilised pürimidiinid ja bitsüklilised 3,4-dihüdropürimidiinid kui rakkude proliferatsiooni inhibiitorid
EP1123295B1 (en) * 1998-10-23 2004-09-29 F. Hoffmann-La Roche Ag Bicyclic nitrogen heterocycles
CZ20021744A3 (cs) 1999-10-21 2002-08-14 F. Hoffmann-La Roche Ag Bicyklické dusíkové heterocykly substituované heteroalkylaminoskupinou jako inhibitory P38 proteinkinázy
US20050202001A1 (en) 2002-04-24 2005-09-15 Han-Mo Koo Enhancement of human epidermal melanogenesis
US7084270B2 (en) * 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
CA2496234A1 (en) 2002-08-21 2004-03-04 Protein Express Co., Ltd. Salt-inducible kinases 2 and use thereof
US7129351B2 (en) 2002-11-04 2006-10-31 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
BR0316680A (pt) 2002-11-28 2005-10-18 Schering Ag Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos
KR20050111636A (ko) 2003-04-10 2005-11-25 에프. 호프만-라 로슈 아게 피리미도 화합물
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
CN1860118A (zh) 2003-07-29 2006-11-08 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
RU2401265C2 (ru) 2004-06-10 2010-10-10 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназы
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
DE602005013248D1 (de) 2004-08-31 2009-04-23 Hoffmann La Roche Amidderivate von 3-phenyldihydropyrimidoä4,5-düpyrimidinonen, deren herstellung und verwendung als pharmazeutische mittel
WO2006024545A1 (en) 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes
US8211929B2 (en) 2004-12-30 2012-07-03 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
AU2006229995A1 (en) 2005-03-25 2006-10-05 Glaxo Group Limited Process for preparing pyrido(2,3-d)pyrimidin-7-one and 3,4-dihydropyrimido(4,5-d)pyrimidin-2(1H)-one derivatives
WO2007071752A2 (en) 2005-12-21 2007-06-28 Novartis Ag Pyrimidinyl aryl urea derivatives being fgf inhibitors
BRPI0711628A2 (pt) * 2006-05-15 2011-12-06 Irm Llc composto, composição farmacêutica, uso e processo para preparação do composto
WO2008060248A1 (en) 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
CA2707046A1 (en) 2007-11-28 2009-06-11 Nathanael S. Gray Small molecule myristate inhibitors of bcr-abl and methods of use
US20100056524A1 (en) 2008-04-02 2010-03-04 Mciver Edward Giles Compound
WO2009152027A1 (en) 2008-06-12 2009-12-17 Merck & Co., Inc. 5,7-dihydro-6h-pyrrolo[2,3-d]pyrimidin-6-one derivatives for mark inhibition
AU2009279936A1 (en) 2008-08-05 2010-02-11 Banyu Pharmaceutical Co., Ltd. Therapeutic compounds
US8586584B2 (en) 2009-10-14 2013-11-19 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
CN102816162B (zh) 2011-06-10 2016-04-27 中国科学院广州生物医药与健康研究院 嘧啶并嘧啶酮类化合物及其药用组合物和应用
EA025881B1 (ru) 2011-09-30 2017-02-28 Онкодизайн С.А. Макроциклические ингибиторы flt3-киназы
EP3569598A1 (en) 2011-11-17 2019-11-20 Dana Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
GB201204384D0 (en) 2012-03-13 2012-04-25 Univ Dundee Anti-flammatory agents
US9296701B2 (en) 2012-04-24 2016-03-29 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
KR20150133767A (ko) 2013-03-15 2015-11-30 온코디자인 에스.에이. 거대고리 염-유도성 키나아제 억제제
SG11201507478VA (en) 2013-03-15 2015-10-29 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
AU2014287209B2 (en) * 2013-07-09 2019-01-24 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
AU2015292818B2 (en) 2014-07-21 2020-01-16 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
WO2016014551A1 (en) 2014-07-21 2016-01-28 Dana-Farber Cancer Institute, Inc. Macrocyclic kinase inhibitors and uses thereof
KR101850282B1 (ko) 2014-11-26 2018-05-31 한국과학기술연구원 단백질 키나아제 저해제로 유용한 헤테로아릴아민 유도체
CN104482860B (zh) 2014-12-05 2017-10-31 浙江大学宁波理工学院 鱼类形态参数自动测量装置和方法
CA3069016A1 (en) 2016-07-05 2018-01-11 The Broad Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
WO2018053373A1 (en) 2016-09-16 2018-03-22 The General Hospital Corporation Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis
AU2018226771B2 (en) * 2017-02-28 2023-11-23 Dana-Farber Cancer Institute, Inc. Uses of pyrimidopyrimidinones as SIK inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014093383A1 (en) * 2012-12-14 2014-06-19 Arrien Pharmaceuticals Llc Substituted 1h-pyrrolo [2,3-b] pyridine and 1h-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (sik2) inhibitors
WO2016023014A2 (en) * 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Uses of salt-inducible kinase (sik) inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A Potent Inhibitor of SIK2, 3, 3’, 7-Trihydroxy-4’-Methoxyflavon (4’-O-Methylfisetin), Promotes Melanogenesis in B16F10 Melanoma Cells;Ayako Kumagai et al.;《PLoS ONE》;20111013;第6卷(第10期);摘要，第1页左栏第1段，图2-图4 *
Development of Chemical Probes for Investigation of Salt-Inducible Kinase Function In Vivo;Thomas B. Sundberg et al.;《ACS Chemical Biology》;20160819;第11卷(第8期);表1 *
Downregulation of SIK2 expression promotes the melanogenic program in mice;Nanao Horike et al.;《Pigment Cell Melanoma Research》;20100831;第23卷(第6期);第809页摘要，第815页左栏第2段 *

Also Published As

Publication number Publication date
JP2023088968A (ja) 2023-06-27
AU2018226771B2 (en) 2023-11-23
CA3054809A1 (en) 2018-09-07
CN111163771A (zh) 2020-05-15
AU2018226771A1 (en) 2019-09-19
BR112019017741A2 (pt) 2020-04-07
US11285158B2 (en) 2022-03-29
JP2020509022A (ja) 2020-03-26
US20200253981A1 (en) 2020-08-13
US20240245695A1 (en) 2024-07-25
EP3589284A4 (en) 2020-12-16
JP7296318B2 (ja) 2023-06-22
KR20190120331A (ko) 2019-10-23
RU2019129727A (ru) 2021-03-30
US20220133736A1 (en) 2022-05-05
US11878019B2 (en) 2024-01-23
EP3589284A1 (en) 2020-01-08
WO2018160774A1 (en) 2018-09-07
RU2019129727A3 (enExample) 2021-07-02

Similar Documents

Publication Publication Date Title
CN111163771B (zh) 嘧啶并嘧啶酮类作为sik抑制剂的用途
EP2970266B1 (en) 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
JP6854762B2 (ja) サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
EP3024327B1 (en) Inhibitors of transcription factors and uses thereof
KR102479822B1 (ko) 선택적 에스트로겐 수용체 분해제 및 이들의 용도
JP6678455B2 (ja) Ｐｒｍｔ５阻害剤およびその使用
JP7590185B2 (ja) Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
JP7660063B2 (ja) サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用
JP2016505597A (ja) Ｐｒｍｔ５阻害剤およびその使用
JP2016505001A (ja) Ｐｒｍｔ５阻害剤およびその使用
HK1225383A1 (zh) 二氮杂环庚烷衍生物及其用途
CN110225914A (zh) 双环脲激酶抑制剂及其用途
JP6788583B2 (ja) 増殖性疾患を処置するためのチアゾリル含有化合物
AU2015300782A1 (en) Uses of salt-inducible kinase (SIK) inhibitors
JP2016505002A (ja) ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するｐｒｍｔ５阻害剤およびその使用
KR20210015833A (ko) 암 줄기 세포를 표적화하는 암 치료
JP2021529174A (ja) Ｄｏｔ１ｌディグレーダーおよびその使用
WO2019222349A1 (en) Compounds for treating dengue virus infections and other infections
BR122024027123A2 (pt) Usos de pirimidopirimidinonas como inibidores de sik
WO2024220852A2 (en) Tead core inhibitors for cancer therapeutics
CN117915918A (zh) 可溶性腺苷酸环化酶(sAC)抑制剂及其用途
WO2022133265A1 (en) Steroidal compound derivatives as therapeutic agents
EP3947382A1 (en) Compounds for uses in pharmacological induction of hbf for treatment of sickle cell disease and beta-thalassemia
HK40004421B (zh) 选择性雌激素受体降解物及其用途
HK1237593A1 (en) Dihydropteridinone derivatives and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant